tirzepatide 1 mg FDA says shortage of GLP-1 is over Tirzepatide Peptide | Research Peptide

When prescribing therapies to patients living with obesity (PwO) the median total weight loss (TWL) gives a good indication of the likely utility of prescription for that individual

Teva Pharmaceuticals has launched the first generic GLP-1 drug for weight loss in adults and adolescents

Consider diet and testing for optimal health

Very interesting paper providing cardiologists point of view on the comparison of semaglutude and tirzepatide They conclude that semaglutide currently remains the most established option for reducing cardiovascular risk in patients with T2DM and obesity with atherosclerotic disease Tirzepatide is particularly well suited when maximal weight reduction represents the primary clinical objective. It needs to be noted that the review was published before publication of results of SURPASS-CVOT were tirzepatide demonstrated non-inferiority vs

Semaglutide exemplifies the fragmented regulatory landscape that exists between frameworks for complex molecules and biologics

Medical-grade peptide therapy in Alexandria, VA for weight loss, muscle growth, inflammation, and skin health